<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle23
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle24
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle25
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle26
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1787114916;
mso-list-template-ids:289952988;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1832133905;
mso-list-template-ids:1908577098;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.lungcancerresearchfoundation.org_assets_uploads_user_2019LCRFPilotGrantProgram-2DRFP.pdf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=OnzDYsTZbAU4aOGpSwqbOpAHmlw7sN0HDqqP3Z5qm6M&s=oxp-9hhFHGkV74xz2LrYWEWTYWN6qX-GOPRJzGYUi8c&e=" target="_blank">Lung Cancer Research Foundation: Pilot Grant Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Lung Cancer Research Foundation’s annual pilot grant program provides funding for research focused on the prevention, diagnosis, treatment and cure of lung cancer. The goal of the program is to fund
innovative projects across the spectrum of basic, translational, and clinical research. We encourage applications for projects investigating a wide variety of topics including:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Improving our understanding of lung cancer biology<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Prevention and screening for early detection<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Identification of new biomarkers and the development of targeted therapies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Development of more effective and safer therapies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Psychosocial research including supportive measures for people with lung cancer and their families<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Quality of care and outcomes research for the improvement of healthcare standards and overall patient outcomes<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">$150,000 for 2-year projects, no IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 14, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: May 31.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.amgenscientificgrants.com_bone_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=OnzDYsTZbAU4aOGpSwqbOpAHmlw7sN0HDqqP3Z5qm6M&s=pUPwhVB-Or80UTm9DHEcqEXf1Y1u8LH8CVlsTNkrb0A&e=" target="_blank">Amgen: Competitive Grant Program in Bone Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Amgen Competitive Grant Program in Bone Research supports innovative research focused on improving the quality of osteoporosis care and patient outcomes. Specific areas of research eligible for funding
through the program include longitudinal data describing long-term (5+ years) osteoporosis care relative to the diverse guidelines; effectiveness of post-fracture care programs demonstrated at a regional or global level (e.g., successfully implemented approaches
and techniques, cost savings realized); delivery of optimal care for osteoporosis in the primary care setting (e.g., patient/physician dialogue, patient disease education, disease recognition); impact of osteoporosis on patient quality of life, including loss
of independence; health system interventions to improve screening rates in high-risk osteoporosis patients; novel tools and approaches beyond bone-density scanning (dual X-ray absorptiometry) to identify high-risk osteoporosis patients; and solutions to improve
patient adherence to their osteoporosis care regimen (e.g., ways to recognize and correct non-compliance).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">$150,000 for 2-year projects; full institutional indirect applied.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 28, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: June 10.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"> <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__philanthropynewsdigest.org_rfps_rfp9906-2Dhubert-2Dand-2Drichard-2Dhanlon-2Dtrust-2Dinvites-2Dresearch-2Dproposals-3Futm-5Fcampaign-3Drfps-257C2019-2D05-2D09-26utm-5Fsource-3Dpnd-26utm-5Fmedium-3Demail&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=OnzDYsTZbAU4aOGpSwqbOpAHmlw7sN0HDqqP3Z5qm6M&s=WTKZpF78OvO4GqcYAg4IDy4qBXfDMs2_Qj9w0V8s8kU&e=" target="_blank">Hubert
and Richard Hanlon Trust: Alcohol Dependency and Abuse</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Hubert and Richard Hanlon Trust funds studies and research on the causes, prevention, and cure of alcohol dependency and abuse as well as the development of effective methods of prevention, treatment,
and a cure for such conditions. In support of this mission, the trust makes annual distributions of income to not-for-profit hospitals, universities, schools, foundations, and rehabilitation centers engaged in such research.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">$100,000 a year for 2-year projects, 10% IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due (by snail mail) June 30, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: June 14.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.damonrunyon.org_for-2Dscientists_application-2Dguidelines_innovation&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=OnzDYsTZbAU4aOGpSwqbOpAHmlw7sN0HDqqP3Z5qm6M&s=4qyARBtVHylfp9nAS60RHfs6eh3FmSLURwNUSmmIMTk&e=" target="_blank">Damon Runyon Cancer Research Foundation Rachleff Innovation Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding
of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain
traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">$200,000 for 2-year projects, no IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Stage 1 application due July 1, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: June 17.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.nationalmssociety.org_For-2DProfessionals_Researchers_Society-2DFunding_Training-2DGrants-2Dand-2DFellowships_Harry-2DWeaver-2DNeuroscience-2DScholar-2DAwards&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=OnzDYsTZbAU4aOGpSwqbOpAHmlw7sN0HDqqP3Z5qm6M&s=3GH8Qe8BWycgl4yVSFgtsYztHr7BelyJNSEuxoE15S4&e=" target="_blank">Harry Weaver Neuroscience
Scholar Awards: National Multiple Sclerosis Society</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The National Multiple Sclerosis Society believes in a world free of MS and is dedicated to ensuring that people affected by MS can live their best lives. To that end, the organization is currently accepting
applications for its Harry Weaver Neuroscience Scholar Award, which is named for Harry Weaver, PhD, known worldwide for his contribution to neuroscience and multiple sclerosis research. Through the program, five-year grants in support of salary and research
will be awarded to highly-qualified candidates who have concluded their research training and begun their academic careers as an independent investigator in an area related to multiple sclerosis. Up to 75 percent of annual salary support may be requested,
not to exceed $75,000 in year one, as well as up to $30,000 for research-associated direct costs, with incremental increases possible in each of the remaining four years.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Pre-applications due August 14, 2019. Full applications due August 21, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: August 7.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__branderbeacons.org_wp-2Dcontent_uploads_BBCR-2DRFP.pdf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=OnzDYsTZbAU4aOGpSwqbOpAHmlw7sN0HDqqP3Z5qm6M&s=mfD7cgpUcl7QG7NRaXZwqnmp-wrYO5iYB_3y5-xEw78&e=" target="_blank">Brander Beacons Cancer Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Brander Beacons Cancer Research is accepting applications from organizations seeking funding for breakthrough research, scientists, and programs to prevent, better treat and cure breast and prostate cancer.
BBCR supports academic research institutions researching tools and techniques that will increase accuracy and improve outcomes in biopsies and tumor removal procedures; identifying ways to improve patient outcomes and access; investing in emerging research
and researchers; serving as an active contributor to the culture of access and innovation in cancer care. BBCR injects critical funds in increments of $5,000 to $25,000 into programs most closely connected to increased cancer prevention, better treatment outcomes,
better access and, ultimately, a cure.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Applications accepted on a rolling basis.
<span style="color:red">Med-RA deadline to receive draft documents is ten business days before submission.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span><span style="color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><span style="font-family:Palatino;color:#954F72">CoM’s
unofficial funding opportunities blog</span></a></span></b><b><span style="font-family:Palatino;color:black">.</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Palatino"> </span><o:p></o:p></p>
</div>
</body>
</html>